Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00262067
Registration number
NCT00262067
Ethics application status
Date submitted
2/12/2005
Date registered
6/12/2005
Date last updated
13/12/2013
Titles & IDs
Public title
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
Query!
Scientific title
A Multicenter, Phase III, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Untreated Metastatic Breast Cancer
Query!
Secondary ID [1]
0
0
BO20094
Query!
Secondary ID [2]
0
0
AVF3694g
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Bevacizumab
Treatment: Drugs - Placebo
Treatment: Drugs - Chemotherapy
Experimental: Bevacizumab + chemotherapy - Patients received bevacizumab 15 mg/kg intravenously (IV) on Day 1 of every 21-day cycle plus one of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
Placebo comparator: Placebo + chemotherapy - Patients received placebo to bevacizumab administered IV on Day 1 of every 21-day cycle + 1 of several standard chemotherapies (taxanes, anthracycline-based regimens, or capecitabine) for metastatic breast cancer.
Treatment: Drugs: Bevacizumab
Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
Treatment: Drugs: Placebo
Placebo consisted of the vehicle for bevacizumab without the antibody.
Treatment: Drugs: Chemotherapy
The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.
Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle
1. Docetaxel 75-100 mg/m\^2 IV
2. Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV
Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle
1. 5-fluorouracil 500 mg/m\^2 IV + epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV
2. 5-fluorouracil 500 mg/m\^2 IV + doxorubicin 50 mg/m\^2 IV + cyclophosphamide 500 mg/m\^2 IV
3. Doxorubicin 50-60 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV
4. Epirubicin 90-100 mg/m\^2 IV + cyclophosphamide 500-600 mg/m\^2 IV
Capecitabine: 1000 mg/m\^2 orally twice daily on Days 1-14 of each 21-day cycle
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Query!
Assessment method [1]
0
0
PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Target lesions should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements by imaging techniques or clinically. All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in total, representative of all involved organs, should be identified as target lesions.
Query!
Timepoint [1]
0
0
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
Query!
Secondary outcome [1]
0
0
Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Query!
Assessment method [1]
0
0
An objective response was defined as a complete response or a partial response determined on two consecutive occasions = 4 weeks apart as determined by the investigator using RECIST. For target lesions, a complete response was defined as the disappearance of all target lesions; a partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. For non-target lesions, a complete response was defined as the disappearance of all non-target lesions; a partial response was defined as the persistence of 1 or more non-target lesions.
Query!
Timepoint [1]
0
0
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
Query!
Secondary outcome [2]
0
0
Duration of Objective Response as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)
Query!
Assessment method [2]
0
0
Duration of objective response was defined as the time from the first tumor assessment that led to a determination of an objective response to the time of disease progression or death due to any cause, whichever occurred first.
Query!
Timepoint [2]
0
0
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
Query!
Secondary outcome [3]
0
0
Overall Survival
Query!
Assessment method [3]
0
0
Overall survival was defined as the time from randomization until death from any cause.
Query!
Timepoint [3]
0
0
Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
Query!
Secondary outcome [4]
0
0
1-year Survival
Query!
Assessment method [4]
0
0
1-year survival was defined as the percentage of patients who were alive 1 year after randomization.
The percentage of patients alive at 1 year was determined using Kaplan-Meier analyses and the 95% confidence intervals were computed using the Brookmeyer-Crowley method.
Query!
Timepoint [4]
0
0
Baseline to the data cut-off of 23 Feb 2009 (up to 3 years, 2 months)
Query!
Secondary outcome [5]
0
0
Progression-free Survival (PFS) as Determined by the Independent Review Committee Using Response Evaluation Criteria in Solid Tumors (RECIST)
Query!
Assessment method [5]
0
0
PFS was defined as the time from randomization to first documented disease progression (PD) as determined by the Independent Review Committee using Response Evaluation Criteria in Solid Tumors (RECIST) or death due to any cause, whichever occurred first.
Query!
Timepoint [5]
0
0
Baseline to the data cut-off date of 31 Jul 2008 (up to 2 years, 7 months)
Query!
Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease.
* Signed Informed Consent Form.
* Age = 18 years.
* For women of childbearing potential, use of accepted and effective method of non-hormonal contraception.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Ability and capacity to comply with study and follow-up procedures.
* For anthracycline cohort only: Adequate left ventricular function at study entry, defined as a left ventricular ejection fraction (LVEF) = 50% by either multigated acquisition (MUGA) scan scan or echocardiography (ECHO).
* For subjects who have received recent radiation therapy, recovery prior to baseline (Day 0) from any significant (Grade = 3) acute toxicity.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Unknown human epidermal growth factor receptor 2 (HER2) status or known HER2-positive status.
* Prior chemotherapy for locally recurrent or metastatic disease.
* Prior hormonal therapy less than 1 week prior to Day 0.
* Prior adjuvant or neoadjuvant chemotherapy within 12 months prior to Day 0.
* For anthracycline cohort only: Prior anthracycline as part of neoadjuvant or adjuvant therapy for localized breast cancer.
* Investigational therapy within 28 days of Day 0.
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study.
* Minor surgical procedures, such as fine needle aspirations or core biopsies, within 7 days prior to Day 0.
* Prior therapy with bevacizumab, sorafenib, sunitinib, or other vascular endothelial growth factor (VEGF) pathway-targeted therapy.
* Known brain or other central nervous system (CNS) metastases.
* Blood pressure of > 150/100 mmHg.
* Unstable angina.
* New York Heart Association (NYHA) Grade II or greater congestive heart failure (CHF).
* History of myocardial infarction within 6 months prior to Day 0.
* History of stroke or transient ischemic attack within 6 months prior to Day 0.
* Clinically significant peripheral vascular disease.
* Evidence of bleeding diathesis or coagulopathy.
* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0.
* Serious non-healing wound, ulcer, or bone fracture.
* Pregnancy (positive serum pregnancy test) or lactation.
* Inadequate organ function, as evidenced by any of the following laboratory values: Absolute neutrophil count < 1500/uL; platelet count < 100,000/uL; total bilirubin > 1.5 mg/dL; alkaline phosphatase, AST, and/or ALT > 2x upper limit of normal (ULN) (> 5x ULN in subjects with known liver or, for alkaline phosphatase elevations, bone involvement); alkaline phosphatase > 2x ULN (> 7x ULN in subjects with known bone involvement); serum creatinine > 2.0 mg/dL; partial thromboplastin time (PTT) and/or either international normalized ratio (INR) or prothrombin time (PT) > 1.5x upper limit of normal (except for subjects receiving anti-coagulation therapy); urine protein/creatinine ratio > 1.0 at screening for U.S. subjects, or urine dipstick for proteinuria >/= 1+ at screening followed by 24-hour urine collection demonstrating > 1 g protein/24 hr for ex-U.S. subjects.
* Uncontrolled serious medical or psychiatric illness.
* Active infection requiring intravenous (iv) antibiotics at Day 0.
* History of other malignancies within 5 years of Day 0 except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal cell carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix (subjects with a history of bilateral breast cancer will be eligible).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
UNKNOWN
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2013
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1237
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Geelong
Query!
Recruitment hospital [2]
0
0
- Malvern
Query!
Recruitment hospital [3]
0
0
- Melbourne
Query!
Recruitment hospital [4]
0
0
- Perth
Query!
Recruitment hospital [5]
0
0
- Southport
Query!
Recruitment hospital [6]
0
0
- Wahroonga
Query!
Recruitment hospital [7]
0
0
- Waratah
Query!
Recruitment hospital [8]
0
0
- Wollongong
Query!
Recruitment postcode(s) [1]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [2]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [3]
0
0
3002 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
6008 - Perth
Query!
Recruitment postcode(s) [5]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [6]
0
0
2076 - Wahroonga
Query!
Recruitment postcode(s) [7]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [8]
0
0
2500 - Wollongong
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Iowa
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kansas
Query!
Country [4]
0
0
Brazil
Query!
State/province [4]
0
0
Porto Alegre
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
Rio de Janeiro
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
Salvador
Query!
Country [7]
0
0
Brazil
Query!
State/province [7]
0
0
Santo Andre
Query!
Country [8]
0
0
Brazil
Query!
State/province [8]
0
0
Sao Paulo
Query!
Country [9]
0
0
Canada
Query!
State/province [9]
0
0
Manitoba
Query!
Country [10]
0
0
Canada
Query!
State/province [10]
0
0
Quebec
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Marseille
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Paris
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Reims
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Saint Herblain
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Strasbourg
Query!
Country [16]
0
0
Greece
Query!
State/province [16]
0
0
Athens
Query!
Country [17]
0
0
Greece
Query!
State/province [17]
0
0
Hania
Query!
Country [18]
0
0
Greece
Query!
State/province [18]
0
0
Heraklion
Query!
Country [19]
0
0
Greece
Query!
State/province [19]
0
0
Patras
Query!
Country [20]
0
0
Greece
Query!
State/province [20]
0
0
Thessaloniki
Query!
Country [21]
0
0
Guatemala
Query!
State/province [21]
0
0
Guatemala City
Query!
Country [22]
0
0
Korea, Republic of
Query!
State/province [22]
0
0
Kyunggi-do
Query!
Country [23]
0
0
Korea, Republic of
Query!
State/province [23]
0
0
Seoul
Query!
Country [24]
0
0
Mexico
Query!
State/province [24]
0
0
Acapulco
Query!
Country [25]
0
0
Mexico
Query!
State/province [25]
0
0
Aguascalientes
Query!
Country [26]
0
0
Mexico
Query!
State/province [26]
0
0
Merida
Query!
Country [27]
0
0
Mexico
Query!
State/province [27]
0
0
Monterrey
Query!
Country [28]
0
0
Netherlands
Query!
State/province [28]
0
0
Amstelveen
Query!
Country [29]
0
0
Netherlands
Query!
State/province [29]
0
0
Apeldoorn
Query!
Country [30]
0
0
Netherlands
Query!
State/province [30]
0
0
Delft
Query!
Country [31]
0
0
Norway
Query!
State/province [31]
0
0
Oslo
Query!
Country [32]
0
0
Panama
Query!
State/province [32]
0
0
Panama City
Query!
Country [33]
0
0
Peru
Query!
State/province [33]
0
0
Callao
Query!
Country [34]
0
0
Philippines
Query!
State/province [34]
0
0
Quezon City
Query!
Country [35]
0
0
Russian Federation
Query!
State/province [35]
0
0
Chelyabinsk
Query!
Country [36]
0
0
Russian Federation
Query!
State/province [36]
0
0
Ivanovo
Query!
Country [37]
0
0
Russian Federation
Query!
State/province [37]
0
0
Kazan
Query!
Country [38]
0
0
Russian Federation
Query!
State/province [38]
0
0
Moscow
Query!
Country [39]
0
0
Russian Federation
Query!
State/province [39]
0
0
Novosibirsk
Query!
Country [40]
0
0
Russian Federation
Query!
State/province [40]
0
0
Obninsk
Query!
Country [41]
0
0
Russian Federation
Query!
State/province [41]
0
0
Ryazan
Query!
Country [42]
0
0
Russian Federation
Query!
State/province [42]
0
0
Samara
Query!
Country [43]
0
0
Russian Federation
Query!
State/province [43]
0
0
St Petersburg
Query!
Country [44]
0
0
Russian Federation
Query!
State/province [44]
0
0
UFA
Query!
Country [45]
0
0
Singapore
Query!
State/province [45]
0
0
Singapore
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
Córdoba
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Elche
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Girona
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
La Coruna
Query!
Country [50]
0
0
Spain
Query!
State/province [50]
0
0
La Laguna
Query!
Country [51]
0
0
Spain
Query!
State/province [51]
0
0
Madrid
Query!
Country [52]
0
0
Spain
Query!
State/province [52]
0
0
Santander
Query!
Country [53]
0
0
Spain
Query!
State/province [53]
0
0
Sevilla
Query!
Country [54]
0
0
Spain
Query!
State/province [54]
0
0
Valencia
Query!
Country [55]
0
0
Spain
Query!
State/province [55]
0
0
Zaragoza
Query!
Country [56]
0
0
Sweden
Query!
State/province [56]
0
0
Gaevle
Query!
Country [57]
0
0
Sweden
Query!
State/province [57]
0
0
Uppsala
Query!
Country [58]
0
0
Sweden
Query!
State/province [58]
0
0
Örebro
Query!
Country [59]
0
0
Taiwan
Query!
State/province [59]
0
0
Tainan
Query!
Country [60]
0
0
Taiwan
Query!
State/province [60]
0
0
Taoyuan
Query!
Country [61]
0
0
Ukraine
Query!
State/province [61]
0
0
Cherkassy
Query!
Country [62]
0
0
Ukraine
Query!
State/province [62]
0
0
Dnipropetrovsk
Query!
Country [63]
0
0
Ukraine
Query!
State/province [63]
0
0
Kiev
Query!
Country [64]
0
0
Ukraine
Query!
State/province [64]
0
0
Lvov
Query!
Country [65]
0
0
Ukraine
Query!
State/province [65]
0
0
Odessa
Query!
Country [66]
0
0
Ukraine
Query!
State/province [66]
0
0
Zaporozhye
Query!
Country [67]
0
0
United Kingdom
Query!
State/province [67]
0
0
Chelsmford
Query!
Country [68]
0
0
United Kingdom
Query!
State/province [68]
0
0
Cottingham
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
Epping
Query!
Country [70]
0
0
United Kingdom
Query!
State/province [70]
0
0
Huddersfield
Query!
Country [71]
0
0
United Kingdom
Query!
State/province [71]
0
0
Nottingham
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
Sheffield
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
Swansea
Query!
Country [74]
0
0
Uruguay
Query!
State/province [74]
0
0
Montevideo
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Genentech, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a Phase III, multicenter, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of bevacizumab in combination with chemotherapy compared with chemotherapy alone in subjects with previously untreated metastatic breast cancer.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00262067
Query!
Trial related presentations / publications
Wedam SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, Tang S, Goldberg KB, Sridhara R, Ibrahim A, Kim G, Kluetz P, McKee A, Pazdur R. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments. J Clin Oncol. 2018 Apr 20;36(12):1225-1231. doi: 10.1200/JCO.2017.74.6917. Epub 2018 Mar 9.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Leonardo Faoro, MD
Query!
Address
0
0
Genentech, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00262067
Download to PDF